טוען...
Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease
Long-acting muscarinic antagonists (LAMAs), along with long-acting β(2)-agonists (LABAs), are the mainstay for treatment of patients with COPD. Glycopyrrolate, or glycopyrronium bromide, like other LAMAs, inhibits parasympathetic nerve impulses by selectively blocking the binding of acetylcholine to...
שמור ב:
| הוצא לאור ב: | Int J Chron Obstruct Pulmon Dis |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6003532/ https://ncbi.nlm.nih.gov/pubmed/29928118 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S162646 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|